Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

Last updated: March 3, 2025
Sponsor: University Hospital, Basel, Switzerland
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Data collection

Digital intervention (DiLCoS)

Clinical Study ID

NCT05781893
2023-00359; th22Schaefert
  • Ages > 18
  • All Genders

Study Summary

The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients in the cohort can also join the Digital Long COVID Study (DiLCoS), a single-arm, cohort-based proof-of-feasibility study that is part of the larger BALCoS. DiLCoS is a intervention substudy designed to evaluate whether doing exercises delivered via a smartphone app (referred as digital intervention) can help with PCC. The digital intervention is a 12-week program that includes different kinds of exercises like breathing exercises, relaxation techniques, and tips on managing fatigue and other symptoms. It also teaches patients how to monitor their activities and energy levels, and provides psychological exercises to cope with negative thoughts and pain. Patients in the cohort complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients diagnosed with PCC will be included. PCC will be defined as:

  • History of confirmed or suspected SARS CoV-2 infection

  • Symptoms usually start within 3 months from the onset of acute SARS CoV-2 infectionwith symptoms and effects that last for at least 2 months

  • Symptoms cannot be explained by an alternative diagnosis

  • signed informed consent is required

Additional Inclusion Criteria for participtation in DiLCoS:

  • A smartphone with a compartible-operating system

  • Separate signed informed consent is required

Exclusion

Exclusion Criteria:

  • Age <18 years

  • Lack of consent to participate in the study

  • Language barriers (lack of sufficient knowledge of German)

  • Lack of general understanding of study procedures

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Data collection
Phase:
Study Start date:
April 20, 2023
Estimated Completion Date:
February 28, 2026

Connect with a study center

  • University Hospital Basel, Department of Psychosomatic Medicine

    Basel, 4031
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.